Testing a new drug for advanced pancreatic cancer
Perform non-GLP and GLP TOX/TK studies, and file a novel drug IND with the FDA for advanced pancreatic cancer patient clinical trials
This study is testing a new drug called FL118 to see if it can safely help people with advanced pancreatic cancer, which currently has few treatment options.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Canget Biotekpharma, LLC NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project ID | NIH-10695608 on NIH RePORTER |
What this research studies
This research focuses on the development of a novel drug called FL118, which targets specific proteins involved in pancreatic cancer. The study will conduct toxicology and toxicokinetics assessments to ensure the drug's safety and effectiveness before filing an application with the FDA for clinical trials. Patients with advanced pancreatic ductal adenocarcinoma (PDAC) will be the primary focus, as this cancer type currently has limited treatment options. The research aims to provide a new therapeutic avenue for patients suffering from this aggressive form of cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with advanced pancreatic ductal adenocarcinoma who have limited treatment options.
Not a fit: Patients with early-stage pancreatic cancer or those with other types of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option for patients with advanced pancreatic cancer, potentially improving survival rates.
How similar studies have performed: While the approach of targeting specific oncogenic proteins is promising, the FL118 drug itself is novel and has not been previously tested in clinical trials for pancreatic cancer.
Where this research is happening
Buffalo, United States
- Canget Biotekpharma, LLC — Buffalo, United States (Active)
Researchers
- Principal investigator: Ling, Xiang — Canget Biotekpharma, LLC
- Study coordinator: Ling, Xiang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.